• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巯基嘌呤脱水的热力学

Thermodynamics of mercaptopurine dehydration.

作者信息

Niazi S

出版信息

J Pharm Sci. 1978 Apr;67(4):488-91. doi: 10.1002/jps.2600670413.

DOI:10.1002/jps.2600670413
PMID:641755
Abstract

The hydrate form of mercaptopurine was shown to undergo peritectic decomposition of its water molecule, localized dissolution, and dehydration around 125 degrees. The anhydrate form was prepared by a thermal method, whose effectiveness was confirmed by X-ray diffraction, NMR spectroscopy, and differential scanning calorimetry. The activation energy for mercaptopurine dehydration calculated by various methods ranged from 45.74 to 63.04 kcal/mole. The dehydration enthalpy was calculated to be 8.27 kcal/mole by differential scanning calorimetry. The solution enthalpy for the hydrate was calculated to be 4.85 kcal/mole from its saturation solubility and differential scanning calorimetry. Anhydrate solubility in water was calculated based on initial dissolution rate data since the anhydrate converts to hydrate in aqueous media. The high degree of stability against interconversion of the hydrate and anhydrate forms and the higher solubility of the anhydrate suggest that use of the anhydrate might improve mercaptopurine bioavailability.

摘要

巯嘌呤水合物形式在约125摄氏度时显示出其水分子的包晶分解、局部溶解和脱水。无水物形式通过热法制备,其有效性通过X射线衍射、核磁共振光谱和差示扫描量热法得到证实。通过各种方法计算得到的巯嘌呤脱水活化能范围为45.74至63.04千卡/摩尔。通过差示扫描量热法计算得到脱水焓为8.27千卡/摩尔。根据水合物的饱和溶解度和差示扫描量热法计算得到其溶解焓为4.85千卡/摩尔。由于无水物在水性介质中会转化为水合物,因此基于初始溶解速率数据计算无水物在水中的溶解度。水合物和无水物形式之间相互转化的高度稳定性以及无水物较高的溶解度表明,使用无水物可能会提高巯嘌呤的生物利用度。

相似文献

1
Thermodynamics of mercaptopurine dehydration.巯基嘌呤脱水的热力学
J Pharm Sci. 1978 Apr;67(4):488-91. doi: 10.1002/jps.2600670413.
2
Solubility and stability of anhydrate/hydrate in solvent mixtures.无水物/水合物在混合溶剂中的溶解度和稳定性。
Int J Pharm. 2006 Sep 14;321(1-2):101-7. doi: 10.1016/j.ijpharm.2006.05.013. Epub 2006 May 16.
3
Improved pharmacokinetics of mercaptopurine afforded by a thermally robust hemihydrate.热稳定性良好的半水合物使巯嘌呤的药代动力学得到改善。
Chem Commun (Camb). 2016 Apr 18;52(30):5281-4. doi: 10.1039/c6cc00424e. Epub 2016 Mar 22.
4
Physical characterization of naproxen sodium hydrate and anhydrate forms.萘普生钠水合物和无水物形式的物理特性
Eur J Pharm Sci. 2001 Dec;14(4):293-300. doi: 10.1016/s0928-0987(01)00179-8.
5
Efficient determination of critical water activity and classification of hydrate-anhydrate stability relationship.
J Pharm Sci. 2025 Jan;114(1):127-135. doi: 10.1016/j.xphs.2024.06.012. Epub 2024 Jun 25.
6
Physical characterization of nedocromil sodium hydrates.奈多罗米钠水合物的物理特性
J Pharm Sci. 1998 Sep;87(9):1052-61. doi: 10.1021/js980106g.
7
Thermal behavior and thermal decarboxylation of 10-hydroxycamptothecin in the solid state.
J Pharm Biomed Anal. 2007 Jan 17;43(2):457-63. doi: 10.1016/j.jpba.2006.07.023. Epub 2006 Aug 24.
8
Preparation and physicochemical properties of niclosamide anhydrate and two monohydrates.氯硝柳胺无水物及两种一水合物的制备与理化性质
Int J Pharm. 2004 Jan 28;269(2):417-32. doi: 10.1016/j.ijpharm.2003.09.035.
9
Structural characterisation and dehydration behaviour of siramesine hydrochloride.盐酸西拉美汀的结构特征和脱水行为。
J Pharm Sci. 2009 Oct;98(10):3596-607. doi: 10.1002/jps.21679.
10
Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.制备无定形呋塞米钠盐可提高溶解度和溶出速率,并导致大鼠口服给药后的 Tmax 更快。
Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):942-51. doi: 10.1016/j.ejpb.2013.09.002. Epub 2013 Sep 27.

引用本文的文献

1
Improved pharmacokinetics of mercaptopurine afforded by a thermally robust hemihydrate.热稳定性良好的半水合物使巯嘌呤的药代动力学得到改善。
Chem Commun (Camb). 2016 Apr 18;52(30):5281-4. doi: 10.1039/c6cc00424e. Epub 2016 Mar 22.
2
Pharmaceutical solids: a strategic approach to regulatory considerations.药物固体:监管考量的战略方法。
Pharm Res. 1995 Jul;12(7):945-54. doi: 10.1023/a:1016241927429.
3
Determination of the relative amounts of anhydrous carbamazepine (C15H12N2O) and carbamazepine dihydrate (C15H12N2O.2H2O) in a mixture by powder x-ray diffractometry.
通过粉末X射线衍射法测定混合物中无水卡马西平(C15H12N2O)和卡马西平二水合物(C15H12N2O·2H2O)的相对含量。
Pharm Res. 1989 Dec;6(12):1017-24. doi: 10.1023/a:1015970218980.
4
Quantitation of the relative amounts of anhydrous carbamazepine (C15H12N2O) and carbamazepine dihydrate (C15H12N2O.2H2O) in a mixture by solid-state nuclear magnetic resonance (NMR).通过固态核磁共振(NMR)对混合物中无水卡马西平(C15H12N2O)和卡马西平二水合物(C15H12N2O·2H2O)的相对含量进行定量分析。
Pharm Res. 1990 Feb;7(2):184-7. doi: 10.1023/a:1015889021145.